A Look At Abiomed Before The $380/Share Buyout From Johnson & Johnson


  • JNJ’s agreed acquisition of ABMD at $380 per share came as a surprise to many healthcare focused investors.
  • ABMD’s speed of innovation around its Impella segment have been a standout all along, as we’ve previously covered.
  • There is still some uncertainty surrounding legal proceedings from selective ABMD shareholders.
  • At this point, it’s prudent to rate ABMD a hold until further clarifications on the deal’s finalization are obtained.

Historic buildings of Wall Street in the financial district of lower Manhattan, New York City


Investment Summary

Since our last publication on Abiomed, Inc. (NASDAQ:ABMD) where we had a buy thesis fully intact, there’s been several notable developments in the company’s growth route. We had previously touched on ABMD’s various strengths in


Data: HBI, Refinitiv Eikon, Koyfin


Data: Seeking Alpha, ABMD, see “earnings”.

Disclosure: I/we have a beneficial long position in the shares of ABMD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Leave a Reply

Your email address will not be published. Required fields are marked *